Abstract: The systems, methods, devices and kits disclosed herein be used to determine the presence and/or level a target analyte(s) in a biological sample, wherein the analyte(s) is associated with a pathogenic (e.g., a viral antigen or whole virus) or otherwise altered physiological condition (e.g., pregnancy). In certain embodiments, the systems, methods, devices and kits provide one or more improved properties relative to the RT-PCT and lateral flow antibody assays known in the art for the detection of SARS-CoV-2, including but not limited to, assay time, ease of use, risk of infection, accuracy, specificity, selectivity, limit of detection of the assay, quantitative detection and the effect of common interferents to the sensor output, cost, simplicity or a combination thereof.

Abstract: Embodiments of a transit ticket system are provided. The transit ticket system may include a mobile computing device configured to (i) download a mobile ticketing application from a ticket management server, the mobile ticketing application including a graphical data sheet, a ticket dictionary, and ticket strings, (ii) receive ticket rendering instructions from the ticket management server in response to completion of a ticket purchase process via the mobile computing device, and (iii) render for display an active ticket on the mobile computing device with data stored on the mobile computing device based on the ticket rendering instructions, the graphical data sheet, ticket dictionary, and ticket strings in response to an activation input command.

Abstract: The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formula (I)-(XXVI) and (III?) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.

Abstract: Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.

Abstract: Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.

Abstract: Embodiments of a transit ticket system are provided. The transit ticket system may include a mobile computing device configured to (i) download a mobile ticketing application from a ticket management server, the mobile ticketing application including a graphical data sheet, a ticket dictionary, and ticket strings, (ii) receive ticket rendering instructions from the ticket management server in response to completion of a ticket purchase process via the mobile computing device, and (iii) render for display an active ticket on the mobile computing device with data stored on the mobile computing device based on the ticket rendering instructions, the graphical data sheet, ticket dictionary, and ticket strings in response to an activation input command.

Abstract: The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formula (I)-(XXVI) and (III?) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.

Abstract: The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formula (I)-(XXVI) and (III?) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.

Abstract: The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formula (I)-(XXVI) and (III?) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.

Abstract: Systems and methods for interaction-based validation of electronic tickets. In some embodiments, the system renders a first visually illustrative scene on an interactive display screen of a mobile device, the first visually illustrative scene responsive to a pre-determined gesture performed at a predetermined location on the interactive display screen. Upon a user interacting with the first visually illustrative scene, an app on the user's mobile device extracts user interaction information. In response to determining that the user interaction information matches with a predetermined gesture performed at the predetermined location, the system renders a second visually illustrative scene on the interactive display screen of the mobile device.

Abstract: The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formula (I)-(XXVI) and (III?) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.

Abstract: The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formulas (I)-(XXVI) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.

Abstract: The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formula (I)-(XXVI) and (III?) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.

Abstract: Systems and methods for interaction-based validation of electronic tickets. In some embodiments, the system renders a first visually illustrative scene on an interactive display screen of a mobile device, the first visually illustrative scene responsive to a pre-determined gesture performed at a predetermined location on the interactive display screen. Upon a user interacting with the first visually illustrative scene, an app on the user's mobile device extracts user interaction information. In response to determining that the user interaction information matches with a predetermined gesture performed at the predetermined location, the system renders a second visually illustrative scene on the interactive display screen of the mobile device.

Abstract: Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.

Abstract: Systems and methods for associating and delivering context-aware content to mobile devices via a programmable trigger that is based upon changes in the mobile device's location. A user's mobile device can interact with trigger-based tracking devices (e.g., Bluetooth beacons, NFC, etc.) which provides location information to the user's mobile device, such location information being relative to the tracking device. Embodiments of the present disclosure also comprise a server that delivers targeted content (e.g., text, graphics, audio, video, etc.) to mobile devices when a user is at a certain geographical location. The content delivered is associated with a context of the user's location which is based in part on the location information received relative to the tracking device. In some embodiments, the content delivery does not require a separate mobile application for the content provider but can be embedded inside transit-related information of a mobile application of a transit agency.

Abstract: The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formulas (I)-(XXVI) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.

Abstract: Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.